Story perspectives

US-UK Trade Deal Boosts Pharma Innovation, NHS Payments Rise

12/4/2025

Center

US-UK Trade Agreement

On December 1, 2025, the United States and the United Kingdom announced a trade agreement exempting UK-origin pharmaceuticals, ingredients, and medical technology from tariffs.
In exchange, the United Kingdom will raise National Health Service (NHS) payments for U.S. medicines by 25% and reform its drug valuation framework to reflect National Institute for Health and Care Excellence (NICE) standards.
The deal aims to boost investment and innovation in both nations.

Left

UK Businesses Struggle

UK small businesses face new tariffs and customs duties on exports to the United States.
Anna Worthington, a UK business owner, says these tariffs complicate keeping prices low.
Despite the hurdles, many UK firms still view the U.S. market as a key opportunity, with about one-fifth exporting goods there.
The United States remains the second most popular destination for U.K. exports after the European Union.

History

Historical Context

The U.S.-U.K. Trade and Investment Framework Agreement, signed in 1998, fostered over $200 billion in bilateral trade, enhancing economic ties. Following the U.K.'s exit from the EU in 2020, negotiations for a free trade agreement have stalled, yet recent initiatives like the Atlantic Declaration in June 2023 aim to strengthen cooperation, particularly in pharmaceuticals and technology, underscoring the importance of transatlantic relations.

1 of 3

US-UK Trade Agreement

On December 1, 2025, the United States and the United Kingdom announced a trade agreement exempting UK-origin pharmaceuticals, ingredients, and medical technology from tariffs.
In exchange, the United Kingdom will raise National Health Service (NHS) payments for U.S. medicines by 25% and reform its drug valuation framework to reflect National Institute for Health and Care Excellence (NICE) standards.
The deal aims to boost investment and innovation in both nations.

1 / 3